Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?

To say that Ginkgo Bioworks' (NYSE: DNA) stock is in a bit of a rough patch doesn't quite capture it. With the price of its shares down by 81% in 2024 alone, many investors are likely wishing they had walked out the door months ago.But with the biotech's ambitious vision for highly automated biopharma manufacturing still unrealized, there may yet be rewards waiting for those who hold on for a bit longer. Or shareholders could just experience even more pain.So is this stock still worth buying, or is it better to look elsewhere for potentially disruptive growth picks?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool